Activation of Ets-1 in cancers is highly associated with chemoresistance [19–22] and linked to poor prognosis in ovarian cancer [23], breast cancer [24], and lung adenocarcinoma [25]. This evidence concerns the gene ETS1 and breast carcinoma.